指南与共识支持与姑息治疗

肿瘤化疗所致血小板减少症中国专家共识(2018版)

[Consensus on clinical diagnosis, treatment and prevention management of chemotherapy induced thrombocytopenia in China(2018)].
指南 / 共识 · Zhonghua Zhong Liu Za Zhi · 2018-01-01

该共识由中国临床肿瘤学会CIT共识专家委员会在2014版基础上更新,针对肿瘤化疗所致血小板减少症(CIT)的临床诊断、治疗和预防管理提出推荐。CIT可导致化疗减量或延迟、需血小板输注,增加费用、降低疗效和生活质量、缩短生存时间;主要治疗包括血小板输注、重组人血小板生成素(rhTPO)和重组人白细胞介素11(rhIL-11)。

要点

  • CIT可致化疗减量、延迟或需血小板输注,增加费用并降低疗效与生存。
  • CIT主要治疗包括血小板输注、rhTPO和rhIL-11。
  • rhTPO对化疗前后血小板增加有效,可促进血小板恢复并减少血小板减少症发生。

核心结论

  • 专家委员会基于近期文献和临床研究更新2018版共识,旨在为CIT患者提供更合理的诊断、治疗和预防方案以维持正常血小板计数。

研究设计与样本

  • 中国临床肿瘤学会(CSCO)CIT共识专家委员会在2014版共识基础上,根据近期文献与临床研究更新制定2018版专家共识。

主要发现

  • CIT是肿瘤化疗常见毒副反应,可能导致化疗药物剂量降低或化疗时间延迟,甚至需要血小板输注。
  • CIT增加患者治疗费用、降低化疗效果和生活质量、缩短生存时间。
  • rhIL-11是最早上市的血小板生成细胞因子,已被证实对治疗血小板减少症有效。
  • rhTPO是c-Mpl配体的一种重组形式,为全长糖化的TPO。
  • rhTPO对化疗前和化疗后血小板增加均有效,能够在中度骨髓抑制方案后促进血小板恢复并减少血小板减少症的发生。

临床怎么用

  • 肿瘤内科医师可依据该共识对CIT进行诊断、治疗和预防管理,以帮助患者维持正常血小板计数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chemotherapy induced thrombocytopenia (CIT) is a common side-effect of chemotherapy in cancer patients, which lead to dose and cycle reduction or chemotherapy delay, or even the need of platelet transfusion. Therefore, CIT significantly increases the cost of treatment, reduces the efficacy of chemotherapy and the quality of life, and shortens the survival time of patients. The main treatments of CIT include transfusion of platelets, recombinant human thrombopoietin (rhTPO), and recombinant human interleukin-11 (rhIL-11). RhIL-11 is the first approved thrombocytopoietic cytokine. Interleukin-11 has been shown to be effective in the treatment of thrombocytopenia. RhTPO is a recombinant full-length glycosylated thrombopoietin, which is a ligand for c-Mpl protein. Several observations indicated that administration of rhTPO before and after chemotherapy might be beneficial to patients, which enhances platelet recovery and reduces thrombocytopenia after moderately myelosuppressive regimens. In recent years, the application of rhTPO in CIT treatment has dramatically changed the management and treatment plan of CIT. The China Society of Clinical Oncology (CSCO) published a consensus on CIT in 2014. Based on this, the expert committee updated "Consensus on clinical diagnosis, treatment and prevention management of chemotherapy induced thrombocytopenia in China (2018)" according to the recent literature and clinical research. The new evidence-based practice consensus for CIT aims to provide more reasonable diagnosis, treatment of prevention regimens for CIT patients to maintain the normal platelet counts. 肿瘤化疗所致血小板减少症(CIT)是肿瘤化疗中常见的毒副反应,有可能导致化疗药物剂量降低或化疗时间延迟,甚至需要血小板输注,因而增加患者的治疗费用、降低化疗效果和患者的生活质量、缩短生存时间。CIT的主要治疗包括输注血小板、重组人血小板生成素(rhTPO)和重组人白细胞介素11(rhIL-11)。rhIL-11是最早上市的血小板生成细胞因子。IL-11已被证实对治疗血小板减少症有效。rhTPO是c-Mpl配体的一种重组形式,是全长糖化的TPO。rhTPO对化疗前和化疗后血小板增加均有效,能够在中度骨髓抑制方案后促进血小板恢复,并减少血小板减少症的发生。近年来,rhTPO在CIT治疗中的应用改变了CIT的诊疗方案。中国临床肿瘤学会CIT共识专家委员会根据CIT的诊疗情况制订了《肿瘤化疗所致血小板减少症诊疗中国专家共识(2014版)》。在此基础上,于2018年,专家委员会根据近期文献及临床研究更新为《肿瘤化疗所致血小板减少症中国专家共识(2018版)》,旨在为中国肿瘤学医师提供更合理的诊疗方案来帮助CIT患者维持正常血小板计数。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Consensus on clinical diagnosis, treatment and prevention management of chemotherapy induced thrombocytopenia in China(2018)]. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 30293399. doi:10.3760/cma.j.issn.0253-3766.2018.09.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。